Currently Browsing CPLRG™ by: Case Name
Browse By: Case Date | Case Number

  1. Pages:
  2. 1
  3. ...
  4. 7
  5. 8
  6. 9
  7. 10
  8. 11
  9. 12
  10. 13
  11. 14
  12. 15
  13. 16
  14. 17

Laboratory Corp. of America Holdings v. Metabolite Laboratories - CPLRG™ 0033 - Mar. 11, 2010

Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc., 599 F.3d 1277 (Fed. Cir. 2010) (GAJARSA & Moore; DYK, dissenting)LabCorpMetabolite03112010

MAJOR ISSUES: declaratory judgment; federal court jurisdiction; cases arising under patent law; jurisdiction determined at outset of suit; prior suit resolving infringement issue Read CPLRG™ 0033

Marrin v. Griffin - CPLRG™ 0035 - Mar. 22, 2010

Marrin v. Griffin, 599 F.3d 1290 (Fed. Cir. 2010) (DYK & Bryson; NEWMAN, dissenting) MarrinGriffin03222010
      
MAJOR ISSUES: claim preamble as limitation; anticipation; preamble as basis for distinguishing prior art; prosecution history; negative limitation Read CPLRG™ 0035

Mayo Collaborative Services v. Prometheus Laboratories, Inc. - CPLRG™ 0079 - Mar. 20, 2012

Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012) (Breyer, J. for unanimous Court).  For the slip opinion, click here: Mayo03202012.USSC

SUMMARY:  CLAIM TO “LAW OF NATURE”; PROCESS STEPS NOT SUFFICIENT TO TRANSFORM CLAIM INTO A PATENT-ELIGIBLE APPLICATION OF A LAW OF NATURE; WELL-UNDERSTOOD, ROUTINE, CONVENTIONAL STEPS PREVIOUSLY USED BY RESEARCHERS IN FIELD; CLAIM TYING UP USE OF UNDERLYING NATURAL LAW AND INHIBITING ITS USE FOR FURTHER DISCOVERY. A patent concerned thiopurine drugs, which are used to treat immune-mediated gastrointestinal disorders. When a thiopurine drug is administered to a patient with the disorder, the patient develops metabolites, including G-TG and 6-MMP. The patent reports the named inventors’ discovery of precise correlations between the level of the metabolites in the patient’s blood and the drug’s efficacy and toxicity. The correlations are useful to physicians for adjusting the drug dosage up or down for a particular patient. The claim at issue recites two steps: (1) administering the drug to a patient with an immune-mediated gastrointestinal disorder and (2) determining the level of the 6-TG metabolite, together with two “wherein” clauses, which recite that a concentration below one specified level (230 pmol) “indicate[s] a need to increase” drug dosage and a concentration above another level (400 pmol) indicates a need to decrease the dosage. A district court held the claim invalid as a “law of nature. The Federal Circuit reversed. HELD: the Federal Circuit erred. The claim is invalid as drawn to a “law of nature,” that is, the relationship between metabolite concentration in blood and thiopurine drug efficacy and toxicity. The recited steps of administering the drug, determining the metabolite level together with the “wherein” indications of a need for dosage adjustment, do not transform the claim into a patent-eligible application of a law of nature because (1) “the steps in the claimed processes (apart from the natural laws themselves) involve well-understood, routine, conventional activity previously engaged in by researchers in the field,” and (2) “upholding the patents would risk disproportionately tying up the use of the underlying natural laws, inhibiting their use in the making of further discoveries.”

COMMENTARY.  For a critical commentary on Mayo, see below. Read CPLRG™ 0079

MBO Laboratories, Inc. v. Becton, Dickinson & Co. - CPLRG™ 0047 - Apr. 12, 2010

MBO Laboratories, Inc. v. Becton, Dickinson & Co., 602 F.3d 1306, 2010 U.S. App. LEXIS 7424 (Fed. Cir. 2010) (GAJARSA, Clevenger & Dyk)MBOLaboratories04122010

MAJOR ISSUES:  reissue patent recapture rule; original claims not invalid; arguments and amendments in related applications Read CPLRG™ 0047

Media Technologies Licensing, LLC v. Upper Deck Co. - CPLRG™ 0027 - Mar. 1, 2010

Media Technologies Licensing, LLC v. Upper Deck Co., 596 F.3d 1334 (Fed. Cir. 2010) (MAYER & Lourie; RADER, dissenting)

MediaTech03012010

MAJOR ISSUES: obviousness; non-technical inventions; secondary considerations; objective evidence; commercial success; lack of nexus; long-felt need Read CPLRG™ 0027

Currently Browsing CPLRG™ by: Case Name
Browse By: Case Date | Case Number

  1. Pages:
  2. 1
  3. ...
  4. 7
  5. 8
  6. 9
  7. 10
  8. 11
  9. 12
  10. 13
  11. 14
  12. 15
  13. 16
  14. 17

©2010 Donald S. Chisum - All Rights Reserved

Website design by Bluegrass Internet Services